Dextromethorphan-Bupropion (Auvelity) for Major Depressive Disorder
The antidepressant that combines dextromethorphan (a cough syrup component) with bupropion to prolong its effects is dextromethorphan-bupropion (Auvelity), FDA-approved in 2022 for major depressive disorder in adults. 1, 2
Mechanism: Why Combine a Cough Medicine with an Antidepressant?
The combination exploits a clever pharmacokinetic interaction:
- Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist with antidepressant properties 3
- Problem: Dextromethorphan is rapidly metabolized by CYP2D6 enzyme, resulting in inconsistent therapeutic levels 1, 4
- Solution: Bupropion is a CYP2D6 inhibitor that blocks dextromethorphan's metabolism, increasing its bioavailability and prolonging its effects 2, 4
This creates both pharmacokinetic synergy (bupropion increases dextromethorphan levels) and pharmacodynamic synergy (bupropion adds norepinephrine/dopamine reuptake inhibition to dextromethorphan's glutamatergic effects) 1, 5.
Clinical Advantages
Rapid onset of action distinguishes this combination from traditional antidepressants:
- Significant improvement observed as early as week 1 of treatment 1, 6
- Traditional SSRIs typically require 4-6 weeks for response 7
The standard dosing is dextromethorphan 45 mg/bupropion 105 mg twice daily 4.
Key Prescribing Considerations
Contraindications and Warnings
- Seizure risk: Contraindicated in patients with seizure disorders, brain metastases, or conditions lowering seizure threshold 8, 9
- MAOIs: Must avoid within 14 days due to hypertensive crisis risk 10, 9
- Opioid therapy: The bupropion component may reduce opioid efficacy; discontinue before procedures requiring opiates 11
- Serotonin syndrome risk: Exercise caution when combining with other serotonergic agents (SSRIs, SNRIs, tramadol, triptans) 12, 10
Common Side Effects
Most frequent adverse effects include dizziness, nausea, headache, diarrhea, somnolence, and dry mouth 13. These are generally manageable and less severe than metabolic effects seen with some alternatives 4.
Black Box Warning
Like all antidepressants, carries FDA black box warning for increased suicidal thoughts/behaviors in patients under age 24 9, 13.
Clinical Context and Alternatives
While dextromethorphan-bupropion represents a novel mechanism, cost and insurance barriers may limit access 6. The evidence base, though positive, is newer compared to established agents. For treatment-resistant depression, this combination offers an alternative to:
- Switching to different antidepressant classes 7
- Augmentation with atypical antipsychotics 11
- Esketamine nasal spray 6
The combination may be particularly valuable for patients requiring rapid symptom improvement or those with comorbid substance use disorders (given bupropion's role in smoking cessation and addiction treatment) 11, 14.